Sharemaestro company-news research for Basilea Pharmaceutica AG (BSLN), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.
EBS
Switzerland
Provisional evidence
Company news sentiment
Latest BSLN news and sentiment
Basilea Pharmaceutica AG
Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.
30-day score50Neutral is 50
Early balanced news score
15/100 evidence confidence
100% direct company focus
1 current stories across 1 publishers
Current company news
Early balanced news score
1 company-specific story are available, but there are not yet enough fresh stories from separate publishers for a firm reading.
Observed headline tone59/100
→
Published 30-day score50/100
Latest source headline
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
GlobeNewswire · 14 Sep 2026 05:15
Older, less relevant and less reliable stories count for less. Confidence is shown separately.
What supports the score
1 current stories are mapped specifically to BSLN.
What limits the score
Only 1 publisher currently contribute to the measured read.
Confidence is 15/100, below the threshold for a firm score.
50/100
News scoreEarly balanced news score
15/100
Confidencethin evidence
100%/100
Company news1 company stories
N/A/100
Story agreementrequires at least 2 stories
News history
Daily score and story count over 30 days
27 Aug11 Sep25 Sep
News scoreStory count50 baseline
Confidence
How reliable the score is
Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.
Amount of evidence0
0.002 after freshness weightingSource breadth20
1 independent publishersCompany relevance100
share tied directly to this companyFreshness14
recency-weighted evidenceAgreement0
requires at least 2 storiesPublisher mix0
less reliance on one publisherPrice and news history
Weekly price and news-score history
Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.
26 completed price weeks13 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
27 Mar23 Jun18 Sep
Weekly close, indexedSentiment score
WeekNews scoreCloseWeekly move
18 Sep 202650CHF 69.0+3.4%
11 Sep 202651CHF 66.699997+4.1%
04 Sep 202652CHF 64.099998-0.6%
28 Aug 202654CHF 64.5-0.2%
21 Aug 202658CHF 64.599998+21.7%
14 Aug 202650CHF 53.099998+2.5%
07 Aug 202650CHF 51.799999-0.2%
31 Jul 202650CHF 51.900002-1.3%
Provisional evidence
News subjects
What is shaping the score
Market update591 stories · 100%
Source mix
Where the evidence comes from
GlobeNewswire591 stories · 100%
Recurring subjects
Subjects appearing most often
Topic structure will appear when classified tags are present in the current feed.
Earlier readings
How the score has changed
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
21 Jun50 neutral20 Sep 13:23
ConstructiveBalanced or withheldCautious
Changes in the stored score
Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.
| Observed | Score | Move | Confidence | Stories | Status |
|---|---|---|---|---|---|
| 20 Sep 13:23 | 50 | -1 | 16/100 (-9) | 1 (-8) | Provisional |
| 14 Sep 23:59 | 51 | -7 | 25/100 (-8) | 9 (-3) | Provisional |
| 21 Aug 23:59 | 58 | +0 | 33/100 (-3) | 12 (+1) | Provisional |
| 18 Aug 23:59 | 58 | +8 | 36/100 (+20) | 11 (+5) | Provisional |
| 05 Aug 23:59 | 50 | +0 | 16/100 (0) | 6 (+1) | Provisional |
| 02 Aug 23:59 | 50 | -1 | 16/100 (-3) | 5 (+1) | Provisional |
| 27 Jul 23:59 | 51 | -1 | 19/100 (-12) | 4 (0) | Provisional |
| 23 Jul 23:59 | 52 | +2 | 31/100 (+31) | 4 (0) | Provisional |
Source headlines
The news behind the score
Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.
#159Tone
GlobeNewswireDirect company coverageScored from headline
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
- Published
- 14 Sep 2026 05:15
- News subject
- Market update
- Why this score
- Strategic partnership
- Company focus
- Main company · 100%
- How it is used
- Direct company coverage
- Story strength
- Low · 35/100
- 30-day weight
- 100% of the score · 11.3d old
- Duplicates
- 1 consolidated
Earlier company news
BSLN news archive
Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.
Older news is kept in the archive
There are 20 older BSLN headlines. Open one page at a time when you need them.
Open older archiveHow the page works
How to read the score
It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.
Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.
Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.
It measures news already published. It is not a forecast, recommendation or price target.